Factor Xa Inhibitor

Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation.

FXIa-IN-14 (Compound 14c) is a FXIa inhibitor with an IC₅₀ value of 15 nM.

Coumafuryl is a kind of coumarin rodenticide. Coumafuryl inhibits the metabolic cycle of vitamin K that causes the interference with protein biosynthesis of vitamin K-dependent coagulant factors (II, VII, IX, and X factors) in the liver.

Betrixaban-d₄ (PRT054021-d₄) is deuterium labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect.

EMD-503982 is an orally available FXa inhibitor.

Cbz-QFR-kbt is a ketone-based benzothiazole ketone inhibitor of TMPRSS2, with an IC₅₀ value of 0.42 nM. Cbz-QFR-kbt also has inhibitory activity against Matriptase, Hepsin, HGFA, and Factor Xa, with IC₅₀ values of 1, 1.3, 85, and 85 nM respectively. Cbz-QFR-kbt shows significant inhibitory effects against SARS-CoV-2 and H1N1 (IC₅₀ = 60 nM). Cbz-QFR-kbt can be used in antiviral research.

WGU55 is a selective and potent reversible type II transmembrane serine protease TMPRSS6 inhibitor with a K_i of 12.15 nM. WGU55 inhibits TMPRSS6 activity with an IC₅₀ of 138 nMin KEK293 cells. WGU55 has a K_i of 3510 nM (SI = 289) against the homologous protease matriptase and a K_i of 5.2 μM against the coagulation key protease Factor Xa. WGU55 can be used for the research of iron overload related diseases, such as hereditary hemochromatosis.

YM-60828-d₃ is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders.

Bacithrocin C is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively.

5-R-Rivaroxaban (Standard) is the analytical standard of 5-R-Rivaroxaban. This product is intended for research and analytical applications. 5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).

AS1468240 is an orally active inhibitor for anticoagulant factor Xa (fXa), that inhibits human fXa with IC₅₀ of 8.7 nM. AS1468240 prolongs the coagulation time in mice.

Lyso-sulfatide (bovine) is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions.

Bacithrocin B is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 84 μM, 17 μM, 1.7 μM, and 0.02 μM, respectively.

FXa-IN-2 (Compound K3) is a reversible FXainhibitor, with an IC₅₀ value of 45.08 μM. FXa-IN-2 can be used in the research of thromboembolic diseases.

Tanogitran is a dual inhibitor targeting Factor Xa and thrombin (thrombin), with K_i values of 26 and 2.7 nM, respectively. Tanogitran exhibits anticoagulant activity and can be used for research in thrombotic diseases.